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Abstract
Introduction: There has been a progressive increase in the incidence of type II diabetes mellitus
cases over the past decade. The availability of a wide variety of oral hypoglycemics has given rise to
a number of adverse effects. In this case report, we describe the case of a patient recently diagnosed
with type II diabetes. He was receiving treatment with glimepiride and experienced rapid onset of
cholestatic liver injury as a side effect, which reversed upon cessation of therapy.
Case presentation: We present the case of a 58-year-old Egyptian man with a recent diagnosis
of type II diabetes mellitus. He presented with a clinical picture of progressive jaundice three days
before admission. Laboratory investigations revealed elevated bilirubin, alkaline phosphatase and
gamma glutamyl transferase levels. Ultrasonography revealed intrahepatic biliary duct dilatation and
two small lymph nodes in the porta hepatis; there was, however, no extrahepatic biliary duct
dilatation or stones in the gall bladder. Abdominal computed tomography excluded pancreatic or
hepatic focal lesions, but the tumor marker CA19-9 was elevated. The progressive improvement in
the patient’s symptomatology and laboratory investigations after admission argued against malignancy.
A thorough and detailed history revealed that the patient had started on a new medication,
glimepiride, five months earlier for the treatment of diabetes mellitus and an improvement was noted
after discontinuation of this oral hypoglycemic and the introduction of insulin therapy to control his
blood sugar.
Conclusion: Drugs are an important, often unrecognized, cause of acute cholestasis. Among the
rare causes responsible for this complication is the sulfonylurea glimepiride. A thorough drug history
is therefore helpful in any case of unexplained cholestasis.
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The incidence of diabetes mellitus has been steadily rising
as a consequence of sedentary lifestyles and poor dietary
habits. A wide variety of oral medications has recently
become available for the management of diabetes
mellitus. Sulfonylureas are one of the drug classes that
act by blocking the pancreatic b-cell potassium channel
causing depolarization and subsequent insulin release.
Sulfonylureas are widely prescribed drugs and are an
infrequent cause of cholestatic liver injury. However, in
this case report, we describe a more unusual presentation
caused by a second generation sulfonylurea, glimepiride.
Case presentation
The patient was a 58-year-old Egyptian man with a 40-year
history of cigarette smoking and a medical history of
chronic cholecystitis. He had been recently diagnosed with
diabetes mellitus. He was started on a treatment regimen
of glimepiride 3 mg daily, as well as undertaking dietary
and lifestyle modifications, resulting in adequate control
of his blood sugar levels.
Five months into therapy, the patient started noticing
fever, rigors and persistent vomiting and attributed these
symptoms to an active flare-up of chronic cholecystitis.
Antibiotic treatment was initiated withnoimprovement in
symptomatology. Two days later, the patient started
noticing yellowish discoloration of his eyes followed by
darkening of his urine and lighter colored stools. The
patient sought medical advice and was admitted to the
hospital for further work-up.
On admission, initial laboratory investigations revealed a
total serum bilirubin of 5 mg/dl, mainly of the direct
fraction. The serum alkaline phosphatase level was
300 U/l, the serum glutamic pyruvic transaminase (SGPT)
level was 90 U/ml and the serum glutamic oxaloacetic
transaminase (SGOT) level was 70 U/ml. SGPT levels were
always higher than SGOT. The patient’s uncontrolled blood
glucose required the replacement of the oral hypoglycemic
with insulin for tight glucose control.
A preliminary diagnosis of cholestatic viral hepatitis vs.




ultrasonographic evaluation showed evidence of dilated
intrahepatic biliary ducts, a contracted gall bladder with
thickened walls and two small lymph nodes present in the
portahepatis.However,therewasnoevidenceofgallstones
or dilatation of the extrahepatic biliary ducts. Magnetic
resonance cholangiopancreatography (MRCP) was per-
formed and revealed no evidence of stones in the common
bile duct and no extrahepatic biliary duct dilatation.
A gastrointestinal carcinoma, a pancreatic carcinoma or a
cholangiocarcinoma were suspected, with possible lym-
phadenopathy in the porta hepatis causing obstructive
jaundice. A computed tomography (CT) scan of the
abdomen confirmed the presence of two lymph nodes in
the porta hepatis and the tumor marker CA19-9 reached
300U/ml, increasing the possibility of a malignancy.
During our patient’s stay in hospital, there was progressive
improvement in his symptomatology as well as the
laboratory investigations, evident by progressive reduc-
tions in the serum bilirubin, alkaline phosphatase, serum
gamma glutamyl transferase (GGT) and tumor marker
CA19-9. This improvement in symptomatology, and the
laboratory investigations and the radiologic evidence
argued against malignancy as an etiology for the described
presentation, which would have otherwise caused pro-
gressive worsening of the patient’s condition. This raised
the possibility that there might be another underlying
cause of cholestasis. After a detailed and thorough review
of the patient’s history, the recent addition of glimepiride
for treatment of his diabetes mellitus was noticed. We
suspected that this newly introduced medication was
responsible for the patient’s presentation. The progressive
improvement in the patient’s condition was attributed to
the discontinuation of his oral hypoglycemic medication
after admission and the start of insulin therapy for the
control of his blood glucose.
Five days after admission, the patient’s general condition
dramatically improved and he was subsequently dis-
charged from hospital with a recommendation of regular
follow-up of serum bilirubin and tumor marker CA19-9.
The patient’s liver profile returned to normal within two
months. The initial ultrasound findings of intrahepatic
bile duct dilatation and lymph nodes enlargement, as well
as theelevated CA 19-9level had resolved and normalized,
this excluded malignancy. Lymph node enlargement can,
however, be explained by the presence of associated
cholangitis or hepatitis and elevated CA19-9 levels can
occur in cholestasis, especially if levels are not so high [1].
One month after discharge, the patient’s laboratory results
revealed normalization of serum bilirubin, hepatic transa-
minases and CA 19-9 levels; however, serum alkaline
phosphatase levels took two months to normalize. After
he was discharged, the patient was prescribed metformin
as a substitute for glimepiride for the control of blood
glucose.
Discussion
Drugs are animportant, often unrecognized,cause of acute
cholestasis. The clinical presentation and laboratory
picture of acute cholestasis resemble that of other
hepatobiliary disorders,for example, calcular obstructive
jaundice. A detailed and thorough drug history should be
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cholestasis. Discontinuation of the offending agent causes
a dramatic improvement in the patient’s symptomatology,
and prevents adverse outcomes [2].
A wide variety of drugs can potentially cause this disorder
including oral contraceptive pills, anabolic steroids,
testosterone, chlorpromazine, fibrates and nifedipine.
Certain antibiotics such as erythromycin, flucloxacillin,
co-amoxicillin, nitrofurantoin and trimethoprim sulfa-
methoxazole [3] should also be considered. Cholestasis
has rarely been encountered in clinical practice in patients
with diabetes receiving sulfonylureas, especially glimepir-
ide. There is only one other article in the literature that
attributed this complication to glimepiride, however, the
diagnosis in that case was confounded by the presence of a
stone in the common bile duct [4].
Patients with acute cholestasis usually present with
pruritis, jaundice (usually olive green discoloration of
the sclera), dark urine and clay colored stools. Laboratory
investigations might show evidence of conjugated hyper-
bilirubinemia, elevated serum GGT and 5’ nucleotidase
levels. Mild elevation of serum transaminases may also be
noticed as a result of the toxic effect of acute bile retention
on hepatocytes or concomitant hepatitis.
Drug-induced cholestasis can be divided into acute and
chronic forms [5]. The acute form is further subdivided
into cholestasis without inflammation (‘bland’ cholesta-
sis), cholestasis with inflammation, and cholestasis with
bile duct injury. The chronic form includes avanishing bile
duct syndrome and a sclerosing cholangitis-like syndrome.
Drugs that cause cholestasis with a bile duct injury are
usually accompanied by additional clinical features such
as fever, rigors, jaundice, and tender hepatomegaly
mimicking that seen in acute cholangitis. Drugs that result
in a vanishing bile duct syndrome may cause rapidly
progressive cholestasis with prolonged periods of jaundice
and occasionally cirrhosis and liver cell failure.
Drug-induced acute cholestasis is a diagnosis of exclusion,
therefore, hepatobiliary imaging is a significant step in the
diagnosis of patients presenting with this disorder.
Hepatobiliary imaging is essential to exclude the presence
of extrahepatic biliary duct dilatation whether due to
pancreatic carcinoma, or a common bile duct stone and to
exclude the presence of any hepatic or pancreatic mass
lesions.
Management of drug-induced cholestasis is focused
mainly on immediate discontinuation of the offending
drug if it is recognized and observing the patient for
clinical and laboratory improvement. Symptomatic treat-
ment for vomiting, fever and especially pruritis should
also commence. Prognosis of drug-induced cholestasis is
usually good and recovery is the rule in most cases,
however, severe cases may progress to liver cirrhosis and
eventually liver failure.
Conclusion
Drugs are animportant, often unrecognized,cause of acute
cholestasis. Drug-induced hepatotoxicity has been infre-
quently reported with the use of sulfonylureas and
especially glimepiride. To the best of our knowledge, this
is the first report in the literature where the diagnosis was
not confounded by any other etiology. Diagnosis should
be considered in any patient with type II diabetes mellitus
on oral hypoglycemic agents presenting with unexplained
cholestatic jaundice. A thorough drug history should be
recorded by the practitioner in any case of unexplained
cholestasis. Recovery is common in these cases provided
that the drug is identified and discontinued.
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